| CAS NO: | 1418205-77-2 |
| 包装 | 价格(元) |
| 1mg | 电议 |
| 5mg | 电议 |
| 10mg | 电议 |
| 50mg | 电议 |
| 100mg | 电议 |
| 生物活性 | Bimekizumab (Anti-Human IL17A/IL-17F Recombinant Antibody) is a humanised monoclonal antibody, can selectively neutralisesIL-17AandIL-17F. Both of them are pro-osteogenic with respect to human periosteum-derived cell (hPDC) differentiation. Thus Bimekizumab blocks the inflammation-driven osteogenic differentiation[1]. | ||
| IC50& Target[1] |
| ||
| 体外研究 (In Vitro) | Bimekizumab (10 μg/mL; 1 h) results dual neutralisation of IL-17A and IL-17F, leads to osteocommitment of hPDCs by AS serum is suppressed[1]. | ||
| 性状 | Liquid | ||
| CAS 号 | 1418205-77-2 | ||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | ||
| 储存方式 | Please store the product under the recommended conditions in the Certificate of Analysis. |
m.cnreagent.com